Melanoma is a serious disease that can advance and spread to other parts of the body, where it becomes difficult to treat.
Food and Drug Administration approved a new drug that uses a genetically engineered cold sore virus to bust up melanoma skin cancer tumors. The FDA based its approval on a study of 436 people with advanced melanoma that had spread. Visible tumors were injected with the drug. The study showed that 16.3 percent of the study participants who received Imlygic experienced a decrease in size of their skin and lymph node lesions, lasting for a minimum of six months. That compared to 2.1 percent patients who did not get the drug.